Blockchain for Cold Chain Traceability: Where It’s Working

Blockchain in Cold Chain: The Hype and the Reality Gap

Between roughly 2017 and 2022, blockchain was proposed as the traceability solution for almost every problem in pharmaceutical distribution: counterfeit prevention, cold chain integrity, recall management, chain-of-custody for advanced therapies, patient consent, clinical supply, and end-to-end serialization. The conference-circuit narrative was consistent. A distributed, tamper-evident ledger would allow every party in the supply chain to see the same version of the truth without trusting any one operator. Temperature excursions would trigger smart contracts. Counterfeits would be shut out by cryptographic authenticity. Recalls would be surgical rather than blanket.

Very little of that vision materialized on the timeline promised. Gartner concluded in mid-2024 that most blockchain-related technologies had moved past the peak of inflated expectations and into the trough of disillusionment, with a Gartner vice president openly speculating that the firm might not publish another blockchain-specific hype cycle at all.¹ A more colorful reading of the same shift from CIO magazine argued that after five years of promises, blockchain enterprise supply-chain use had “crawled along” from disillusionment without ever meaningfully climbing the slope of enlightenment.²

The important thing for pharma leaders is that this disillusionment did not extend uniformly. A small number of production networks kept building. They tended to share a specific profile: a compliance-driven use case, an industry-wide governance body, and a problem that any single operator would have struggled to solve alone.

There is a second, quieter reason those networks survived. The original blockchain pitch conflated three separable properties: distributed consensus, cryptographic verifiability, and shared operational trust. Only the third of those actually mattered for most pharmaceutical use cases. Once teams stopped treating the first two as ends in themselves, and instead treated the technology as a governance instrument for coordinating competitors, the design conversations became productive. That reframing is what separates the deployments still running from the deployments that were quietly wound down between 2021 and 2024.

It also explains why the surviving deployments look nothing like the initial roadmaps. There are no public blockchains, no tokens, no consumer-facing traceability apps. What exists is permissioned Hyperledger Fabric or Quorum networks, tight participant vetting, off-chain data storage with on-chain hashes and pointers, and highly specific verification workflows. The elegant end-state marketing was aspirational. What runs in production is functional plumbing that solves a defined coordination problem.

These numbers frame the stakes but do not settle the architectural question. A twenty-billion-dollar annual loss category is enough to justify serious investment in almost any credible mitigation. The question is whether the credible mitigation involves blockchain, or whether the same money spent on IoT sensors, warehouse management modernization, and better validated packaging would produce faster returns. In most cases the honest answer is the second one. In a small but growing set of cases, blockchain adds something the alternatives cannot.

Where Blockchain Has Actually Delivered

Stripping away the marketing, three deployment categories account for essentially all of the blockchain cold chain traceability that is running in production today. Each one has a clear structural reason for the choice.

Multi-party consortium supply chains under regulatory scrutiny

Blockchain earns its keep when a network of manufacturers, distributors, dispensers, and regulators need to share a common record and no participant is willing to let a competitor host the database. The United States prescription drug supply, under the Drug Supply Chain Security Act (DSCSA), is the canonical example. The final DSCSA milestone came into full enforcement on November 27, 2024, requiring interoperable, package-level electronic exchange of transaction data across the entire prescription supply chain.⁵ The MediLedger Network, built by Chronicled and running on a customized Hyperledger Fabric implementation, now processes more than 1.6 billion DSCSA-related transactions per year across 27 pharmaceutical manufacturers representing roughly 80 percent of U.S. prescription drug volume, plus 18 wholesale distributors and hundreds of dispensers.⁴

High-value biologics with acute cold chain sensitivity

Biologics, mRNA products, and specialty injectables tolerate very little temperature deviation. Peer-reviewed work has documented that fluctuations of just one to two degrees Celsius can render some biologics or insulin therapeutically inert.⁶ When a shipment is worth six or seven figures and the recipient is unwilling to administer a product whose cold chain history cannot be independently verified, tamper-evident custody records have a legitimate role. Frameworks that combine blockchain with IoT sensors and machine learning have been proposed and prototyped for vaccine cold chains, with peer-reviewed publications describing smart-contract-triggered quarantine when a sensor detects an excursion.⁷

Cell and gene therapies with vein-to-vein chain of custody

Autologous cell and gene therapies are the strongest structural fit for blockchain-based traceability that has been proposed to date. A JMIR-published feasibility protocol described the requirements for a needle-to-needle chain of custody: patient cells travel from clinic to manufacturing site and back as a personalized product, and any break in identity, temperature, or handling invalidates the therapy for a specific human patient.⁸ Because the product cannot be substituted and the process crosses multiple institutions, a shared, immutable record has direct clinical utility rather than only regulatory value.

The DSCSA Context: Compliance Reshaped the Investment Case

The DSCSA arc explains a great deal about why some blockchain investments matured while others withered. The 2013 legislation set out a decade-long trajectory culminating in interoperable, unit-level, electronic traceability. The final enforcement date, delayed once, landed in late 2024. All actors in the U.S. supply chain must now exchange package-level events using the EPCIS 1.3 standard, with early adopters already migrating to EPCIS 2.0 JSON-LD during 2025 and 2026.⁵

DSCSA did not mandate blockchain. It mandated interoperability, package-level detail, and verifiability. That distinction is important. Most of the market took a non-blockchain path. Serialization platforms from TraceLink, Antares Vision’s rfXcel, and Axway, along with proprietary systems inside major wholesalers, deliver DSCSA-compliant EPCIS exchange over existing EDI infrastructure and are broadly assessed as market leaders.⁹ These are centralized systems with API-based verification routers. They meet the letter of the law without invoking a distributed ledger.

The MediLedger consortium chose blockchain because a large group of competitors could not agree to route their verification traffic through any one vendor’s centralized system, particularly one that might see who was querying which SKUs at what volume. Zero-knowledge proofs and permissioned Hyperledger Fabric allowed distributors to verify a product identifier against the manufacturer’s master data without either party leaking commercial intelligence.⁴ A well-designed blockchain solved a governance problem that a well-designed database could not.

TraceLink itself submitted an interoperable blockchain network solution to the FDA’s DSCSA pilot program and ran a Digital Recalls Network pilot with 22 supply-chain members, exploring blockchain as an overlay to its existing serialization repository rather than a replacement.¹⁰ The initiative has not displaced the platform’s centralized architecture, but it is instructive: even the market leader in traditional serialization sees a defined role for distributed ledger technology in specific, cross-enterprise scenarios like coordinated recalls.

A Case-Study Review of Real Deployments

The following section walks through the deployments that have moved beyond pilot into operating status, or that offer instructive lessons even where they stalled.

MediLedger Network (Chronicled)

MediLedger is the most substantial production blockchain deployment in pharma. Chronicled, the operator, built the network on a permissioned Hyperledger Fabric substrate to serve the U.S. prescription drug supply chain. The DSCSA Verification Router allows an authorized distributor or dispenser to query a product’s authenticity against manufacturer-held master data in sub-second time, with the response and the query itself logged as tamper-evident audit records. Zero-knowledge proofs prevent the routing infrastructure from learning either party’s commercial detail.⁴

Independent reporting confirms that Chronicled’s pilot participants included seven of the top ten pharmaceutical manufacturers, all three major U.S. wholesalers, Walgreens, Walmart, and FedEx.¹¹ The FDA received the pilot’s final report through the DSCSA pilot project program.¹² With three big wholesalers and roughly half the top twenty manufacturers participating in the production network, coverage now exceeds 95 percent of U.S. resold prescription drug volume by unit.¹³

TraceLink Trace Histories and Digital Recalls Network

TraceLink’s approach demonstrated that a serialization market leader can integrate a distributed ledger overlay without abandoning its centralized platform. The Digital Recalls Network pilot used blockchain as a shared, permissioned coordination layer for recall notifications, allowing manufacturers, distributors, and dispensers to reconcile which units of a recalled lot were where without any party needing to trust the others’ internal systems.¹⁰ The Trace Histories workstream explored blockchain as a “gather upon request” mechanism, keeping full transaction data at the edges while using the ledger to establish that the requested data existed and had not been altered.

Modum and IoT-linked cold chain monitoring

Modum, a Swiss startup, was one of the earlier movers in pairing IoT temperature sensors with a blockchain ledger for pharmaceutical cold chain. Peer-reviewed and industry coverage describes a solution in which a shipment’s sensor data is written to a shared ledger, providing both the operator and the recipient with tamper-evident evidence that the payload remained within its allowable temperature envelope during transit.⁷ Modum’s model is instructive because it made explicit the boundary of blockchain’s contribution. The sensor was the source of temperature truth. The ledger was the source of custody truth. Neither alone was sufficient.

FarmaTrust (Zoi platform)

FarmaTrust’s most cited deployment is a pilot with the Mongolian government to trace the national pharmaceutical supply chain and combat counterfeit medicines.¹⁴ That case is meaningful precisely because it is in an emerging market where counterfeit rates run as high as 30 percent and the domestic institutional capacity to run a national serialization program is thinner than in the U.S. or EU.¹⁵ Blockchain reduced the reliance on any single domestic operator and gave international donors and manufacturers an audit trail they could verify independently.

Cell and gene therapy pilots

The most operationally rigorous blockchain feasibility work has come out of the advanced therapies space. A JMIR-published research protocol described the design of a blockchain-based platform for chain of custody in autologous cell and gene therapy, focused on standardized manufacturing and needle-to-needle traceability of temperature-sensitive personalized products.⁸ Industry reporting through 2025 and 2026 confirms that blockchain is gaining traction specifically inside the cell and gene therapy supply chain software category, where the tolerance for chain-of-custody ambiguity is essentially zero.¹⁶

Common Failure Patterns and Where Plain Databases Are Better

The blockchain projects that quietly disappeared or never left proof-of-concept tell you as much as the successful ones. A recurring set of failure modes cuts across almost all of them.

Single-entity supply chains treating blockchain as a database

The most common failure is treating a distributed ledger as an upgrade to internal record-keeping. When a manufacturer owns the packaging line, the 3PL, and the distribution warehouse, or when a single dominant integrated distributor runs end-to-end custody, there is no trust problem for blockchain to solve. A well-designed relational or document database on modern cloud infrastructure will index, query, and audit faster and cheaper than any distributed ledger. Structural analysis of blockchain adoption in pharma explicitly identifies competing network standards, onboarding costs, data privacy conflicts, transaction volume limits, and regulatory ambiguity as the reasons blockchain has failed to achieve broad industry-wide adoption on the distribution side.¹⁷

Consortiums that never resolve governance

Blockchain projects that gathered a dozen stakeholders around a table and started building code before agreeing on rules of engagement invariably failed. The technology cannot resolve a governance vacuum. The MediLedger pattern of first defining data-sharing rules, verification workflows, and privacy boundaries, then implementing them, is uncommon. Most consortiums moved directly to technology and stalled when the first sensitive data-sharing question surfaced.

Sensor-blind ledgers

Blockchain records the assertion that a temperature reading was captured. It does not attest to whether the sensor was working correctly, calibrated recently, or placed in the coldest corner of the payload. Deployments that treated the ledger as if it verified physical truth, rather than digital custody of digital records, produced audit trails that looked rigorous but concealed the same risks as unblocked cold chains. The Modum model of pairing sensor certification with ledger custody is the honest architecture. Sensor-blind ledgers are theater.

Interoperability collapse

Multiple competing blockchain networks emerged during the DSCSA build-up. Trading partners did not join every network, and cross-network verification remained brittle. This is a familiar pattern in enterprise blockchain generally: fragmentation among consortium projects reintroduces the coordination problem that blockchain was supposed to solve. Coverage remains uneven across the wholesale and dispensing tiers.¹⁸

Chasing counterfeit prevention as the primary case

Blockchain, on its own, does not prevent counterfeits. It verifies the authenticity of a serial number against a manufacturer’s records. If a counterfeiter clones a legitimate serial number and moves the fake through unauthorized channels, blockchain will not detect the physical fake. Prevention requires physical anti-counterfeit measures (holograms, spectroscopy, RFID tamper-evident seals) that generate the data blockchain then attests to. Deployments that led with counterfeit-prevention marketing without pairing the ledger to physical authentication found themselves with an elegant chain of digital custody around a physically compromised product.¹⁵

Underestimating onboarding effort

The technical cost of joining a permissioned blockchain network is trivial compared with the operational cost. New participants have to certify their master data, integrate their WMS or ERP with the network’s API, train dispensing or warehouse staff on new workflows, and pass a data-quality audit before they can transact meaningfully. In practice this can take six to nine months even for a mid-sized distributor. Pilots that projected linear growth in participation almost always fell behind their forecasts, and several networks stalled because the second wave of members never converted from letters of intent to production connections.

A Decision Framework: Blockchain or Traditional Traceability

The strategic question for pharma and biotech leaders is not whether blockchain is a good technology in the abstract. It is whether blockchain earns its way into a specific traceability architecture over the credible alternative. The following framework is what we work through with clients when the question comes up.

A decision that passes all six tests is a candidate for blockchain. A decision that fails any of the first four is a stronger candidate for a well-architected centralized platform. Failing five or six of the tests indicates that neither approach is well suited yet and that the problem needs restructuring before technology is chosen.

A useful test we apply late in the evaluation is what we call the “operator-substitution” question. If the network’s operator were replaced tomorrow with a competitor, would the participants still trust the record? For MediLedger the answer is yes because the consensus and cryptographic verification do not depend on Chronicled’s continued goodwill. For most centralized platforms the answer is no, and that is often fine because the operator has a contract and a regulator holding it to account. The question is not which answer is correct in the abstract. The question is which answer the participants need in order to sign the data-sharing agreement in the first place.

The Road Ahead: What to Watch in 2026 and Beyond

Three developments over the next several years will determine whether blockchain-based cold chain traceability expands beyond its current niches or remains confined to them.

Conclusion

Blockchain for pharmaceutical cold chain traceability is neither the transformation that its early advocates promised nor the wasted investment that its critics now claim. It is a specialized tool with a well-defined niche. Where multiple parties need to share the same custody record without trusting a common operator, where the shipments are high-value and clinically consequential, and where governance has been resolved before code is written, blockchain earns its place. Where any of those conditions is missing, a centralized platform with strong access controls and IoT sensor integration is faster, cheaper, and easier to change. The honest posture for pharma leaders is to reject the framing that treats blockchain as either a default or a taboo, and instead assess it against the same functional and financial tests that any other architectural choice deserves.

Sakara Digital works with pharma and biotech organizations building cold chain, traceability, and quality architectures for biologics, cell and gene therapies, and specialty distribution networks. If you are evaluating a blockchain-based approach, wrestling with DSCSA readiness, or comparing serialization platforms against distributed ledger alternatives, we are happy to have that conversation and offer an independent perspective on where to start.